{"id":"adalimumab-treatment-arm","safety":{"commonSideEffects":[{"rate":"12-26","effect":"Injection site reactions"},{"rate":"7-17","effect":"Upper respiratory tract infections"},{"rate":"12","effect":"Headache"},{"rate":"0.1-0.3","effect":"Tuberculosis reactivation"},{"rate":"1-3","effect":"Serious infections"}]},"_chembl":{"chemblId":"CHEMBL1201580","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Adalimumab blocks TNF-α, a key pro-inflammatory cytokine involved in immune-mediated diseases. By preventing TNF-α from binding to its receptors on immune cells and other tissues, it suppresses the inflammatory cascade and reduces disease activity in autoimmune and inflammatory conditions.","oneSentence":"Adalimumab is a monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:18:23.536Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Crohn's disease"},{"name":"Ulcerative colitis"},{"name":"Ankylosing spondylitis"},{"name":"Psoriatic arthritis"},{"name":"Psoriasis"},{"name":"Juvenile idiopathic arthritis"}]},"trialDetails":[{"nctId":"NCT06926478","phase":"PHASE1","title":"Subconjunctival Humira for Boston Keratoprosthesis","status":"NOT_YET_RECRUITING","sponsor":"Massachusetts Eye and Ear Infirmary","startDate":"2026-06-01","conditions":"Penetrating Keratoplasty, Multiple Graft Failure, Ocular Cicatricial Pemphigoid","enrollment":8},{"nctId":"NCT07348588","phase":"PHASE1, PHASE2","title":"Intravitreal Adalimumab in Inherited and Degenerative Retinal Diseases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centro de Pesquisa Rubens Siqueira","startDate":"2024-03-01","conditions":"Retinitis Pigmentosa (RP), Extensive Macular Atrophy With Pseudodrusen (EMAP)","enrollment":30},{"nctId":"NCT04527380","phase":"PHASE3","title":"A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2021-04-13","conditions":"Juvenile Psoriatic Arthritis, Enthesitis Related Arthritis","enrollment":101},{"nctId":"NCT06996652","phase":"PHASE2","title":"An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD)","status":"NOT_YET_RECRUITING","sponsor":"Yale University","startDate":"2026-04","conditions":"REM Sleep Behavior Disorder","enrollment":108},{"nctId":"NCT06100744","phase":"PHASE3","title":"A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab","status":"RECRUITING","sponsor":"AbbVie","startDate":"2024-07-08","conditions":"Juvenile Psoriatic Arthritis","enrollment":40},{"nctId":"NCT03412747","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"UCB Biopharma SRL","startDate":"2018-01-26","conditions":"Chronic Plaque Psoriasis, Moderate to Severe Plaque Psoriasis","enrollment":478},{"nctId":"NCT03895203","phase":"PHASE3","title":"A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis","status":"COMPLETED","sponsor":"UCB Biopharma SRL","startDate":"2019-04-03","conditions":"Psoriatic Arthritis","enrollment":852},{"nctId":"NCT01000441","phase":"PHASE4","title":"Rotation or Change of Biotherapy After First Anti-TNF Treatment Failure for Rheumatoid Arthritis","status":"COMPLETED","sponsor":"University Hospital, Strasbourg, France","startDate":"2009-12-23","conditions":"Rheumatoid Arthritis","enrollment":300},{"nctId":"NCT02586831","phase":"PHASE1, PHASE2","title":"Diabetes Islet Preservation Immune Treatment","status":"WITHDRAWN","sponsor":"Camillo Ricordi and Jay Skyler","startDate":"2024-06-01","conditions":"Diabetes Mellitus, Type 1, Hypoglycemia, Autoimmune Diseases","enrollment":""},{"nctId":"NCT06528431","phase":"PHASE4","title":"Design and Evaluation of an Individualized Biodrug Tapering Strategy Based on Biodrug Dosage: the MONITORA Study","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2024-12-19","conditions":"Arthritis, Rheumatoid","enrollment":180},{"nctId":"NCT05590455","phase":"PHASE2","title":"Tnf Inhibitors to Reduce Mortality in HIV-1 Infected PAtients With Tuberculosis meNIngitis","status":"RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2023-04-11","conditions":"Tuberculous Meningitis, HIV I Infection","enrollment":130},{"nctId":"NCT03739853","phase":"PHASE4","title":"Severe Psoriatic Arthritis - Early intervEntion to Control Disease: the SPEED Trial","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2019-05-14","conditions":"Psoriatic Arthritis","enrollment":192},{"nctId":"NCT05535738","phase":"PHASE2, PHASE3","title":"Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation","status":"RECRUITING","sponsor":"Wei-Che Ko","startDate":"2022-11-15","conditions":"Skin Inflammation, Allergic Contact Dermatitis","enrollment":45},{"nctId":"NCT07151937","phase":"PHASE2","title":"A Study of LAD191 in Adults With Hidradenitis Suppurativa","status":"NOT_YET_RECRUITING","sponsor":"Almirall, S.A.","startDate":"2025-09","conditions":"Hidradenitis Suppurativa","enrollment":200},{"nctId":"NCT02929251","phase":"PHASE2","title":"Randomized Trial Comparing Efficacy of Adalimumab, Anakinra and Tocilizumab in Non-infectious Refractory Uveitis","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2017-06-29","conditions":"Uveitis, Biotherapy","enrollment":112},{"nctId":"NCT04985435","phase":"PHASE4","title":"Better After CHoosing. Randomly Allocated or Patient Preference Based Treatment With Filgotinib or TNFi in RA (BACH)","status":"RECRUITING","sponsor":"R.Bos","startDate":"2021-05-12","conditions":"Rheumatoid Arthritis","enrollment":100},{"nctId":"NCT04891640","phase":"NA","title":"Biologic Abatement and Capturing Kids' Outcomes and Flare Frequency in Juvenile Spondyloarthritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Hospital of Philadelphia","startDate":"2021-11-11","conditions":"Juvenile Spondyloarthritis","enrollment":164},{"nctId":"NCT06390436","phase":"PHASE4","title":"Therapeutic Drug Monitoring-baSed adalimuMab De-escalatiOn in nOn-infecTious cHronic Uveitis","status":"NOT_YET_RECRUITING","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2025-06","conditions":"Uveitis, Chronic Disease","enrollment":320},{"nctId":"NCT05414201","phase":"PHASE4","title":"A Study to Assess Change in Disease Activity and Adverse Events of Adalimumab in Chinese Participants Requiring High Dose Corticosteroids for Active Non-Infectious Intermediate, Posterior, or Pan-Uveitis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2022-07-07","conditions":"Non-infectious Intermediate Posterior- or Pan-uveitis","enrollment":87},{"nctId":"NCT05108259","phase":"PHASE1","title":"To Compare the Pharmacokinetics and Safety of PBP1502 and Humira in Healthy Subjects","status":"RECRUITING","sponsor":"Prestige Biopharma Limited","startDate":"2022-03-30","conditions":"Healthy Volunteers","enrollment":324},{"nctId":"NCT03261102","phase":"NA","title":"TDM Guided Early Optimization of ADAL in Crohn's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"waqqas.afif","startDate":"2017-01-17","conditions":"Crohn Disease, Drug Monitoring, Inflammatory Bowel Diseases","enrollment":200},{"nctId":"NCT03816397","phase":"PHASE4","title":"Adalimumab in JIA-associated Uveitis Stopping Trial","status":"COMPLETED","sponsor":"Nisha Acharya","startDate":"2020-03-15","conditions":"Uveitis, JIA","enrollment":87},{"nctId":"NCT05599347","phase":"PHASE2","title":"Pre-treatment With Azithromycin to Reduce Immunogenicity to to Anti-TNF Agents in Patients With Crohn's Disease","status":"RECRUITING","sponsor":"Rambam Health Care Campus","startDate":"2023-04-24","conditions":"Crohn's Disease Relapse, Biological Substance; Adverse Effect","enrollment":180},{"nctId":"NCT05884242","phase":"PHASE1","title":"A Study of Adalimumab on Inflammatory Mediators Following a Systemic Endotoxin Challenge","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2023-05-22","conditions":"Healthy","enrollment":20},{"nctId":"NCT06849908","phase":"PHASE2","title":"Baricitinib in the Treatment of Intestinal Behçet's Syndrome","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2024-11-08","conditions":"Behcet Syndrome, Intestinal Type","enrollment":56},{"nctId":"NCT04909801","phase":"PHASE3","title":"A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to Methotrexate","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2021-09-15","conditions":"Rheumatoid Arthritis","enrollment":338},{"nctId":"NCT00783510","phase":"","title":"Juvenile Idiopathic Arthritis (JIA) Registry","status":"COMPLETED","sponsor":"AbbVie","startDate":"2008-07-11","conditions":"Juvenile Idiopathic Arthritis, JIA","enrollment":849},{"nctId":"NCT05299242","phase":"PHASE2, PHASE3","title":"The Anti-Freaze-F Study- \"Anti-TNF for Treatment of Frozen Shoulder - a Feasibility Study\"","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2022-07-21","conditions":"Frozen Shoulder","enrollment":9},{"nctId":"NCT06498089","phase":"PHASE4","title":"A Randomized, Controlled, Open-label, Multicenter Clinical Trial Comparing the Efficacy and Safety of a Precision Treatment Regimen Based on Clinical-molecular Phenotypes with a Conventional Treatment Regimen in the Treatment of Patients with Active Takayasu's Arteritis","status":"RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2024-06-28","conditions":"Takayasu Arteritis","enrollment":124},{"nctId":"NCT05640245","phase":"PHASE2","title":"Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic Arthritis","status":"COMPLETED","sponsor":"MoonLake Immunotherapeutics AG","startDate":"2022-12-13","conditions":"Arthritis, Psoriatic","enrollment":207},{"nctId":"NCT02451748","phase":"PHASE4","title":"IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA","status":"COMPLETED","sponsor":"University of Illinois at Chicago","startDate":"2015-08","conditions":"Rheumatoid Arthritis","enrollment":32},{"nctId":"NCT06333210","phase":"PHASE3","title":"Study of the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of BCD-180 in Patients With Axial Spondyloarthritis (LEVENTA)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Biocad","startDate":"2023-12-25","conditions":"Axial Spondyloarthritis","enrollment":421},{"nctId":"NCT05322473","phase":"PHASE2","title":"Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis Suppurativa","status":"COMPLETED","sponsor":"MoonLake Immunotherapeutics AG","startDate":"2022-04-25","conditions":"Hidradenitis Suppurativa","enrollment":234},{"nctId":"NCT04230213","phase":"PHASE3","title":"A Comparative Study Between PF-06410293 and Humira® in Combination With Methotrexate in Participants With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2020-01-13","conditions":"Rheumatoid Arthritis","enrollment":455},{"nctId":"NCT02660580","phase":"PHASE3","title":"MSB11022 in Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"Fresenius Kabi SwissBioSim GmbH","startDate":"2016-02-16","conditions":"Psoriasis, Plaque Type Psoriasis, Moderate to Severe Plaque Psoriasis","enrollment":443},{"nctId":"NCT04360785","phase":"NA","title":"Effect of Two Methotrexate in Sync With the First Adalimumab to Prevent the Immunisation Anti Ada in Spondyloarthritis","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2020-11-11","conditions":"Spondyloarthritis","enrollment":124},{"nctId":"NCT02760407","phase":"PHASE3","title":"Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease","status":"COMPLETED","sponsor":"R-Pharm International, LLC","startDate":"2016-06-06","conditions":"Rheumatoid Arthritis","enrollment":1648},{"nctId":"NCT05995691","phase":"PHASE1","title":"Study to Determine the Pharmacokinetic (PK) Bioequivalence of ABP 501 and Adalimumab (Humira®) in Healthy Adult Japanese Participants","status":"COMPLETED","sponsor":"Amgen","startDate":"2014-11-24","conditions":"Healthy Volunteers","enrollment":179},{"nctId":"NCT05909852","phase":"PHASE1","title":"A Study Comparing the Pharmacokinetics (PK) of ABP 501 40 mg/0.4 mL (ABP 501-HCF) and ABP 501 40 mg/0.8 ml (ABP 501-LCF) in Healthy Adult Participants","status":"COMPLETED","sponsor":"Amgen","startDate":"2021-07-23","conditions":"Adalimumab","enrollment":372},{"nctId":"NCT03619876","phase":"PHASE4","title":"Effects of Abatacept on Myocarditis in Rheumatoid Arthritis","status":"TERMINATED","sponsor":"Columbia University","startDate":"2019-07-10","conditions":"Rheumatoid Arthritis, Myocardial Inflammation","enrollment":11},{"nctId":"NCT04089514","phase":"","title":"A Real-world Study of Imraldi® Use","status":"COMPLETED","sponsor":"Biogen","startDate":"2019-06-30","conditions":"Arthritis, Rheumatoid (RA), Axial Spondyloarthritis (axSpA), Arthritis, Psoriatic (PsA)","enrollment":1000},{"nctId":"NCT05683054","phase":"PHASE4","title":"A Non-inferiority Study on Dose Reduction of Adalimumab in Psoriasis Patients Who Are Overtreated","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2020-08-11","conditions":"Psoriasis","enrollment":19},{"nctId":"NCT03662919","phase":"","title":"One-year Persistence to Treatment of Participants Receiving Flixabi or Imraldi: a French Cohort Study","status":"COMPLETED","sponsor":"Biogen","startDate":"2018-07-02","conditions":"Arthritis, Rheumatoid, Spondylitis, Ankylosing, Arthritis, Psoriatic","enrollment":2274},{"nctId":"NCT04224194","phase":"PHASE3","title":"Auto-injector Real Life Handling in Patients","status":"COMPLETED","sponsor":"Alvotech Swiss AG","startDate":"2019-11-04","conditions":"RA","enrollment":107},{"nctId":"NCT03983876","phase":"PHASE1","title":"PK, Safety and Tolerability Study of AVT02 (Adalimumab) Pre-filled Syringe (PFS) vs, AVT02 Autoinjector (AI)","status":"COMPLETED","sponsor":"Alvotech Swiss AG","startDate":"2019-07-01","conditions":"Phase 1","enrollment":207},{"nctId":"NCT03849313","phase":"PHASE1","title":"Pharmacokinetics, Safety and Tolerability Study of AVT02 to EU-approved and US-licensed Humira (Adalimumab)","status":"COMPLETED","sponsor":"Alvotech Swiss AG","startDate":"2019-03-20","conditions":"Healthy Volunteers","enrollment":390},{"nctId":"NCT02714322","phase":"PHASE3","title":"MYL-1401A Efficacy and Safety Comparability Study to Humira®","status":"COMPLETED","sponsor":"Mylan Inc.","startDate":"2015-06","conditions":"Psoriasis, Arthritis, Psoriatic","enrollment":294},{"nctId":"NCT02619552","phase":"","title":"Impact of Medical Treatment on Sexual Function in Patients With Crohn's Disease","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2011-08","conditions":"Crohn's Disease, IBD","enrollment":50},{"nctId":"NCT05164198","phase":"PHASE4","title":"REduCed Dose of TNFi in Patients With Ankylosing SpondyliTis (RECAST)","status":"UNKNOWN","sponsor":"Hanyang University Seoul Hospital","startDate":"2022-01-15","conditions":"Ankylosing Spondylitis, Axial Spondyloarthritis","enrollment":448},{"nctId":"NCT01373151","phase":"PHASE2","title":"Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2011-06","conditions":"Rheumatoid Arthritis","enrollment":418},{"nctId":"NCT04859088","phase":"NA","title":"Biologics and Partial Enteral Nutrition Study","status":"RECRUITING","sponsor":"NHS Greater Glasgow and Clyde","startDate":"2021-09-20","conditions":"Crohn Disease","enrollment":80},{"nctId":"NCT03970824","phase":"PHASE1","title":"To Compare the Pharmacokinetics and Safety of CT-P17 and Humira in Healthy Subjects","status":"COMPLETED","sponsor":"Celltrion","startDate":"2019-05-31","conditions":"Healthy","enrollment":312},{"nctId":"NCT04171414","phase":"PHASE3","title":"A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Celltrion","startDate":"2019-09-09","conditions":"Rheumatoid Arthritis","enrollment":62},{"nctId":"NCT05119452","phase":"NA","title":"Screening for Flare After b/tsDMARD Discontinuation in Rheumatoid Arthritis","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2022-03","conditions":"Rheumatoid Arthritis","enrollment":85},{"nctId":"NCT02256462","phase":"PHASE4","title":"Pediatric Crohn's Disease AdalImumab Level-based Optimization Treatment (PAILOT) Trial","status":"COMPLETED","sponsor":"Schneider Children's Medical Center, Israel","startDate":"2015-05-01","conditions":"Crohn's Disease","enrollment":82},{"nctId":"NCT02092467","phase":"PHASE4","title":"Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-03-14","conditions":"Arthritis, Rheumatoid","enrollment":4372},{"nctId":"NCT03210259","phase":"PHASE3","title":"The VOLTAIRE-X Trial Looks at the Effect of Switching Between Humira® and BI 695501 in Patients With Plaque Psoriasis","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2017-07-10","conditions":"Psoriasis","enrollment":259},{"nctId":"NCT04643483","phase":"PHASE3","title":"A Study to Test Efficacy, Safety, and Pharmacokinetics of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Crohn's Disease","status":"WITHDRAWN","sponsor":"UCB Biopharma SRL","startDate":"2021-06","conditions":"Crohn's Disease","enrollment":""},{"nctId":"NCT04514796","phase":"PHASE1","title":"Pharmacokinetics, Safety, Tolerability, and Immunogenicity of Two Formulations of SB5 in Healthy Male Subjects","status":"COMPLETED","sponsor":"Samsung Bioepis Co., Ltd.","startDate":"2020-08-13","conditions":"Healthy","enrollment":188},{"nctId":"NCT04045782","phase":"PHASE4","title":"Evaluation of the Safety and Effectiveness of Switching From Humira® to Imraldi® in Flanders","status":"COMPLETED","sponsor":"Pieter Dewint, MD PhD","startDate":"2019-08-19","conditions":"Inflammatory Bowel Diseases","enrollment":130},{"nctId":"NCT01893996","phase":"PHASE4","title":"Study of Adalimumab to Lower Cardiovascular Risk in RA Patients With Well Controlled Joint Disease","status":"COMPLETED","sponsor":"Jonathan Graf","startDate":"2013-07","conditions":"Rheumatoid Arthritis, Cardiovascular Disease","enrollment":63},{"nctId":"NCT03311464","phase":"PHASE3","title":"A Study Assessing the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Participants in Japan","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-10-27","conditions":"Pyoderma Gangrenosum","enrollment":22},{"nctId":"NCT02745080","phase":"PHASE3","title":"Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-04-03","conditions":"Psoriatic Arthritis","enrollment":853},{"nctId":"NCT01387802","phase":"","title":"Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2011-06-29","conditions":"Ankylosing Spondylitis","enrollment":722},{"nctId":"NCT01602302","phase":"PHASE4","title":"Ultrasound and Withdrawal of Biological DMARDs in Rheumatoid Arthritis","status":"TERMINATED","sponsor":"Medical University of Graz","startDate":"2012-06","conditions":"Rheumatoid Arthritis","enrollment":40},{"nctId":"NCT03220841","phase":"PHASE4","title":"Stricture Definition and Treatment (STRIDENT) Drug Therapy Study","status":"UNKNOWN","sponsor":"St Vincent's Hospital Melbourne","startDate":"2017-10-09","conditions":"Crohn Disease, Inflammatory Bowel Diseases, Stricture; Bowel","enrollment":78},{"nctId":"NCT02353780","phase":"PHASE4","title":"Mechanistic Studies of B- and T-Cell Function in RA Patients Treated With TNF Antagonists, Tocilizumab, or Abatacept","status":"TERMINATED","sponsor":"Dr. Larry W. Moreland","startDate":"2015-03","conditions":"Rheumatoid Arthritis (RA)","enrollment":10},{"nctId":"NCT03849404","phase":"PHASE3","title":"Efficacy, Safety, and Immunogenicity of AVT02 With Moderate-to-Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"Alvotech Swiss AG","startDate":"2019-02-20","conditions":"Plaque Psoriasis","enrollment":413},{"nctId":"NCT04439929","phase":"PHASE1","title":"Comparative Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of Adalimumab in Healthy Subjects","status":"COMPLETED","sponsor":"Turgut İlaçları A.Ş.","startDate":"2019-07-17","conditions":"Healthy Participants","enrollment":168},{"nctId":"NCT02808975","phase":"PHASE4","title":"Safety and Efficacy of Adalimumab (Humira) for Hidradenitis Suppurativa (HS) Peri-Surgically","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-07-18","conditions":"Hidradenitis Suppurativa (HS)","enrollment":206},{"nctId":"NCT02904902","phase":"PHASE3","title":"Open-label Study of Adalimumab in Japanese Subjects With Hidradenitis Suppurativa","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-09-06","conditions":"Hidradenitis Suppurativa","enrollment":15},{"nctId":"NCT04147026","phase":"NA","title":"Prediction Medical Device for Rheumatoid Arthritis (PREDIRA)","status":"UNKNOWN","sponsor":"Hospital San Carlos, Madrid","startDate":"2019-12-16","conditions":"Arthritis, Rheumatoid","enrollment":180},{"nctId":"NCT02675023","phase":"PHASE1","title":"Assessment of Pharmacokinetics and Safety of M923 Administered Via Auto-injector or Prefilled Syringe, in Healthy Subjects","status":"COMPLETED","sponsor":"Momenta Pharmaceuticals, Inc.","startDate":"2016-01","conditions":"Healthy","enrollment":603},{"nctId":"NCT02198651","phase":"PHASE4","title":"A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected Via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remission Rheumatoid ArThritis (RA) Subjects","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-01-05","conditions":"Rheumatoid Arthritis, Musculoskeletal and Connective Tissue Diseases","enrollment":149},{"nctId":"NCT02565810","phase":"PHASE2","title":"An Multicentre Clinical Study to Evaluate the Usability and Safety of the Pre-filled Pen and Pre-filled Syringe of SB5 in Subjects With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Samsung Bioepis Co., Ltd.","startDate":"2015-09","conditions":"Rheumatoid Arthritis","enrollment":49},{"nctId":"NCT01505491","phase":"PHASE1","title":"Pharmacokinetics and Safety Study of BI 695501 in Healthy Subjects","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2011-12-01","conditions":"Healthy","enrollment":193},{"nctId":"NCT02850965","phase":"PHASE3","title":"Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2016-08-17","conditions":"Psoriasis","enrollment":318},{"nctId":"NCT02144714","phase":"PHASE1","title":"Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of SB5 in Healthy Subjects","status":"COMPLETED","sponsor":"Samsung Bioepis Co., Ltd.","startDate":"2014-05","conditions":"Healthy","enrollment":189},{"nctId":"NCT02045979","phase":"PHASE1","title":"Pharmacokinetics and Safety in Healthy Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2014-01-31","conditions":"Healthy","enrollment":327},{"nctId":"NCT01866592","phase":"PHASE4","title":"Vascular Inflammation in Psoriasis - Extension Study","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2013-04","conditions":"Psoriasis, Cardiovascular Disease","enrollment":81},{"nctId":"NCT02722044","phase":"PHASE3","title":"Usability of an AI for M923 in Subjects With Moderate to Severe RA","status":"COMPLETED","sponsor":"Momenta Pharmaceuticals, Inc.","startDate":"2016-04","conditions":"Rheumatoid Arthritis","enrollment":33},{"nctId":"NCT01609205","phase":"PHASE4","title":"Doppler Evaluation in RA Patients After Adalimumab.","status":"COMPLETED","sponsor":"Hamed Rezaei","startDate":"2012-10","conditions":"Rheumatoid Arthritis","enrollment":60},{"nctId":"NCT01927757","phase":"PHASE4","title":"Evaluating Etanercept Use in Patients With Moderate to Severe Rheumatoid Arthritis Who Have Lost Response to Adalimumab","status":"TERMINATED","sponsor":"Amgen","startDate":"2013-05-06","conditions":"Moderate to Severe Rheumatoid Arthritis","enrollment":90},{"nctId":"NCT02137226","phase":"PHASE3","title":"BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2015-01-26","conditions":"Arthritis, Rheumatoid","enrollment":645},{"nctId":"NCT02016105","phase":"PHASE3","title":"Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Adalimumab (GP2017) and Humira","status":"COMPLETED","sponsor":"Sandoz","startDate":"2013-12","conditions":"Plaque Type Psoriasis","enrollment":465},{"nctId":"NCT02016482","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-01","conditions":"Nail Psoriasis, Plaque Psoriasis","enrollment":217},{"nctId":"NCT01674413","phase":"PHASE3","title":"Calprotectin-Directed Humira® Maintenance Therapy (CADHUM)","status":"WITHDRAWN","sponsor":"Peter Higgins","startDate":"2013-10","conditions":"Crohn's Disease","enrollment":""},{"nctId":"NCT01899755","phase":"PHASE1","title":"A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability, Immunogenicity, and Pharmacodynamics (PD) of GSK2800528 in Healthy Subjects.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-07-10","conditions":"Psoriasis","enrollment":45},{"nctId":"NCT02114931","phase":"PHASE3","title":"Long-term Safety and Efficacy of ABP 501 in Subjects With Moderate to Severe Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Amgen","startDate":"2014-04","conditions":"Arthritis, Rheumatoid","enrollment":467},{"nctId":"NCT01400516","phase":"PHASE4","title":"Teriparatide for Joint Erosions in Rheumatoid Arthritis: The TERA Trial","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2011-08","conditions":"Rheumatoid Arthritis","enrollment":26},{"nctId":"NCT01691014","phase":"","title":"Formation of Antibodies and Subsequent Prediction of Clinical Response in Patients With Rheumatoid Arthritis Treated With Four TNF Blocking Agents","status":"TERMINATED","sponsor":"Pfizer","startDate":"2013-04","conditions":"Rheumatoid Arthritis (RA)","enrollment":79},{"nctId":"NCT01162421","phase":"PHASE4","title":"A Canadian Study to Evaluate Early Use of Adalimumab After Methotrexate Failure in Early Rheumatoid Arthritis","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2010-09","conditions":"Rheumatoid Arthritis","enrollment":77},{"nctId":"NCT02489760","phase":"PHASE4","title":"Etanercept Versus Adalimumab in the Treatment of Patients With Ankylosing Spondylitis. A Switch Study","status":"UNKNOWN","sponsor":"Chung Shan Medical University","startDate":"2008-07","conditions":"Ankylosing Spondylitis","enrollment":30},{"nctId":"NCT00298272","phase":"PHASE2","title":"Safety and Tolerability of Rituxan With Methotrexate and Etanercept or Methotrexate and Adalimumab in Patients With Active Rheumatoid Arthritis","status":"TERMINATED","sponsor":"Biogen","startDate":"2006-05","conditions":"Rheumatoid Arthritis","enrollment":54},{"nctId":"NCT02237729","phase":"PHASE1","title":"A Study Of PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira) In Healthy Subjects (REFLECTIONS B538-07))","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-09","conditions":"Healthy Subjects","enrollment":362},{"nctId":"NCT01704599","phase":"PHASE1, PHASE2","title":"Addition of Modulators of Homocysteine to Adalimumab Therapy in the Treatment of Moderate to Severe Plaque Psoriasis","status":"TERMINATED","sponsor":"Wayne State University","startDate":"2009-01","conditions":"Psoriasis","enrollment":8},{"nctId":"NCT01505855","phase":"PHASE4","title":"Efficacy Study of Pneumococcal Vaccination in Crohn's Disease","status":"COMPLETED","sponsor":"Kyunghee University Medical Center","startDate":"2011-12","conditions":"Crohn's Disease","enrollment":197},{"nctId":"NCT01881464","phase":"","title":"Anti TNF α Improves Endothelial Dysfunction in IBD Patients","status":"UNKNOWN","sponsor":"Carmel Medical Center","startDate":"2014-05","conditions":"Crohn's Disease","enrollment":20},{"nctId":"NCT01185288","phase":"PHASE4","title":"A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2010-09","conditions":"Rheumatoid Arthritis","enrollment":309},{"nctId":"NCT01870986","phase":"PHASE1","title":"Study Of PF-06410293 And Adalimumab In Healthy Subjects (REFLECTIONS B538-01)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-05","conditions":"Healthy","enrollment":210}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":15,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Humira, Adalimumab"],"phase":"marketed","status":"active","brandName":"Adalimumab treatment arm","genericName":"Adalimumab treatment arm","companyName":"Medical University of Vienna","companyId":"medical-university-of-vienna","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Adalimumab is a monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling. Used for Rheumatoid arthritis, Crohn's disease, Ulcerative colitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}